InvestorsHub Logo
Followers 5
Posts 91
Boards Moderated 0
Alias Born 09/02/2020

Re: JBWIN post# 321957

Friday, 01/29/2021 12:13:57 PM

Friday, January 29, 2021 12:13:57 PM

Post# of 424170
A quick example is available from today's CHMP highlights:

Name of medicine Nexpovio
INN selinexor
Marketing-authorisation applicant Karyopharm Europe GmbH
Therapeutic indication Treatment of relapsed and refractory multiple myeloma
More information Nexpovio: Pending EC decision - to be published on Monday 1 February 2021

Karyopharm markets Selinexor as Xpovio is the United States.


XPOVIO® (selinexor) | Healthcare Professional Sitewww.xpoviopro.com
Learn more about XPOVIO® (selinexor), (XVd regimen) the first and only XPO1 inhibitor that fights specific hematologic cancers, like relapsed and refractory ...
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News